FDG-PET in Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy Toxicity: A Systematic Review
Authors:
- Akram Al-IbraheemAkram Al-Ibraheem
- Ahmed Saad AbdlkadirAhmed Saad Abdlkadir
- Egesta LopciEgesta Lopci
- Sudqi AllouziSASudqi Allouzi
- Diana PaezDPDiana Paez
- Maryam AlkuwariMAMaryam Alkuwari
- Mohammad MakosehMMMohammad Makoseh
- Fuad NovruzovFNFuad Novruzov
- Sharjeel UsmaniSharjeel Usmani
- Kamal Al-RabiKAKamal Al-Rabi
- Asem MansourAMAsem Mansour
Open Access
Abstract
The utilization of chimeric antigen receptor (CAR) T-cell therapy to target cluster of differentiation (CD)19 in cancer immunotherapy has been a recent and significant advancement. Although this approach is highly specific and selective, it is not without complications. Therefore, a systematic review was conducted to assess the current state of positron emission tomography (PET) in evaluating the adverse effects induced by CAR T-cell therapy. A thorough search of relevant articles was performed in databases such as PubMed, Scopus, and Web of Science up until March 2024. Two reviewers independently selected articles and extracted data, which was then organized and categorized using Microsoft Excel. The risk of bias and methodological quality was assessed. In total, 18 articles were examined, involving a total of 753 patients, in this study. A wide range of utilities were analyzed, including predictive, correlative, and diagnostic utilities. While positive outcomes were observed in all the mentioned areas, quantitative analysis of the included studies was hindered by their heterogeneity and use of varying PET-derived parameters. This study offers a pioneering exploration of this promising field, with the goal of encouraging further and more focused research in upcoming clinical trials.Keywords
This publication has 47 references indexed in Scilit:
- [18F]FDG PET/CT for prognosis and toxicity prediction of diffuse large B-cell lymphoma patients with chimeric antigen receptor T-cell therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- Metabolic parameters predict survival and toxicity in chimeric antigen receptor T‐cell therapy‐treated relapsed/refractory large B‐cell lymphomaHematological Oncology, 2023
- Baseline [18F]FDG PET features are associated with survival and toxicity in patients treated with CAR T cells for large B cell lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2023
- PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphomaeJHaem, 2023
- CAR t-cell therapy in BOlogNa–NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON–NEUTRAL): proposed protocol and results from an Italian studyJournal of Neurology, 2023
- Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practiceeJHaem, 2021
- [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studiesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicityJournal of Neurology, 2021
- Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapyAnnals of Hematology, 2021
- Glial injury in neurotoxicity after pediatric CD19‐directed chimeric antigen receptor T cell therapyAnnals of Neurology, 2019